69 results
6-K
EX-99.1
IPHA
Innate Pharma
14 May 24
Innate Pharma Reports First Quarter 2024 Business Update And Financial Results
6:07am
of independent experts, determined to be related to aggressive disease progression and lacutamab unrelated.
Peripheral T Cell lymphoma (PTCL
6-K
EX-99.1
eajh657fq5g5 47uke
21 Mar 24
Summary of Consolidated Financial Statements and Notes
9:20am
6-K
EX-99.1
xu70tfy2q any9cj8mw
21 Mar 24
Innate Pharma reports Full Year 2023 Financial Results and Business Update
6:01am
6-K
EX-1.1
5hnbv7n6h82jla8sk
6 Feb 24
Current report (foreign)
5:05pm
6-K
EX-5.1
jz9tn7 zrvvs40
6 Feb 24
Current report (foreign)
5:05pm
424B5
p5bffyur4q vdf
6 Feb 24
Prospectus supplement for primary offering
5:00pm
6-K
9iyevx5 abo17c
5 Jan 24
Innate Pharma S.a. 6-K
6:09am
6-K
EX-99.1
g9hdo3g4 u77
4 Jan 24
FDA lifts partial clinical hold on lacutamab clinical programFatal case related to disease progression and unrelated to the treatment
6:01am
F-3
EX-5.1
4pslv2s
20 Dec 23
Shelf registration (foreign)
4:45pm
F-3
nn3un 5d69p7ymxm2ddx
20 Dec 23
Shelf registration (foreign)
4:45pm
F-3
EX-3.1
72s0n4f1 mqo4q
20 Dec 23
Shelf registration (foreign)
4:45pm
F-3
EX-23.1
u811y2b5tb7mz44msi8
20 Dec 23
Shelf registration (foreign)
4:45pm
6-K
EX-1.1
aazb0e 9k04k3e2kf6
26 Apr 23
Current report (foreign)
4:02pm
424B5
xzqead
26 Apr 23
Prospectus supplement for primary offering
4:01pm
20-F/A
EX-4.9
1ioy0yu28ss6
20 Apr 23
Annual report (foreign) (amended)
8:47am